Novartis Hit By Canakinumab NSCLC Miss
Interleukin-1 Beta Inhibitor Fails To Improve Survival
The Swiss firm's canakinumab has proved to be an effective treatment for several inflammation-driven rare conditions but disappointment from the CANOPY-2 trial suggests that cancer will follow cardiovascular as an indication where the therapy falls by the wayside.
You may also be interested in...
In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.
Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.
Novartis is taking its unexpected CANTOS cancer findings for canakinumab and running with them to Phase III in an adjuvant lung cancer setting that is broader that AstraZeneca's PACIFIC study.